Mind-body therapy via videoconferencing in patients with neurofibromatosis

Neurology

Volumn 87, Issue 8, 2016, Pages 806-814

  Vranceanu, Ana Maria ^a   Riklin, Eric ^a   Merker, Vanessa L ^a   Macklin, Eric A ^a   Park, Elyse R ^a   Plotkin, Scott R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALTERNATIVE MEDICINE; ANXIETY; ARTICLE; CONTROLLED STUDY; COPING BEHAVIOR; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; OUTCOME ASSESSMENT; PAIN INTENSITY; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; PROGRAM EFFICACY; PROGRAM FEASIBILITY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SOCIAL ENVIRONMENT; SOCIAL INTERACTION; VIDEOCONFERENCING; WORLD HEALTH ORGANIZATION; COMPLICATION; FEASIBILITY STUDY; GROUP THERAPY; MIDDLE AGED; NEUROFIBROMATOSES; PATIENT ATTITUDE; PROCEDURES; TELEMEDICINE;

ADULT; ANXIETY; DEPRESSION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MIND-BODY THERAPIES; NEUROFIBROMATOSES; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACCEPTANCE OF HEALTH CARE; PSYCHOTHERAPY, GROUP; QUALITY OF LIFE; SINGLE-BLIND METHOD; TELEMEDICINE; VIDEOCONFERENCING;

EID: 84983551878     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003005     Document Type: Article

References (31)

1. Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol 2013; 114: 257-262.
2. Wang DL, Smith KB, Esparza S, et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med 2012; 14: 977-982.
3. Vranceanu AM, Merker VL, Plotkin SR, Park ER. The Relaxation Response Resiliency Program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol 2014; 120: 103-109.
4. Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a systematic review of the literature. Am J Med Genet A 2010; 152A: 1136-1156.
5. Elliott J, Chapman J, Clark DJ. Videoconferencing for a veteran's pain management follow-up clinic. Pain Manag Nurs 2007; 8: 35-46.
6. Haozous E, Doorenbos AZ, Demiris G, et al. Role of telehealth/videoconferencing in managing cancer pain in rural American Indian communities. Psychooncology 2012; 21: 219-223.
7. Carlson LE, Lounsberry JJ, Maciejeweski O, Wright K, Collacutt V, Taenzer P. Telehealth-delivered group smoking cessation for rural and urban participants: feasibility and cessation rates. Addict Behav 2012; 37: 108-114.
8. Mahaffey B, Gonzalez A, Reffi A, Kotov R, Bromet E, Luft B. Designing a randomized controlled trial for PTSD and comorbid health problems: the development of a credible comparison treatment. Poster presented at the 48th Annual Association for Behavioral and Cognitive Therapies Conference; November 2014; Philadelphia
9. Skevington SM, Lofty M, O'Connell KA. The World Health Organization's WHOQOL-BREF Quality of Life Assessment: psychometric properties and results of the international field trial. A report from the WHOQOL Group. Qual Life Res 2004; 13: 299-310.
10. WHOQOL Group. Field Trial WHOQOL-100. February 1995: Facet Definitions and Questions. Geneva: WHO (MNH/PSF/95.1.B); 1995.
11. Den Oudsten BL, Ziglstra WP, De Vries J. The minimal clinical important difference in the World Health Organization Quality of Life Instrument-100. Support Care Cancer 2013; 21: 1295-1301.
12. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282: 1737-1744.
13. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092-1097.
14. Wolters PL, Martin S, Merker VL, et al. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology 2013; 81: S6-S14.
15. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the Brief Pain Inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004; 20: 309-318.
16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-381.
17. Park ER, Traeger L, Vranceanu AM, et al. The development of a patient-centered program based on the relaxation response: the Relaxation Response Resiliency Program (3RP). Psychosomatics 2013; 54: 165-174.
18. Dusek J, Otu HH, Wohlhueter AL, et al. Genomic counter-stress changes induced by the relaxation response. PLoS One 2008; 3: e2576.
19. Vranceanu AM, Shaefer JR, Saadi AF, et al. The Relaxation Response Resiliency Enhancement Program in the management of chronic refractory temporomandibular joint disorder: results from a pilot study. J Musculoskelet Pain 2013; 3: 224-230.
20. Bhasin MK, Dusek JA, Chang BH, et al. Relaxation response induces temporal transcriptome changes in energy metabolism, insulin secretion and inflammatory pathways. PLoS One 2013; 8: e62817.
21. Vranceanu AM, Gonzalez A, Niles H, et al. Exploring the effectiveness of a modified comprehensive mind-body intervention for medical and psychological symptom relief. Psychosomatics 2014; 55: 386-391.
22. Denninger JW, Bhasin M, Huffman J, et al. Clinical and genomic effects of a relaxation response-based mind-body intervention in stage I hypertension. J Altern Complement Med 2014; 20: A54.
23. Kuo B, Bhasin M, Jacquart J, et al. Genomic and clinical effects associated with a relaxation response mind-body intervention in patients with irritable bowel syndrome and inflammatory bowel disease. PLoS One 2015; 10: e0123861.
24. Miller KM, Chad-Friedman E, Haime V, et al. The effectiveness of a brief mind-body intervention for treating depression in community health center patients. Glob Adv Health Med 2015; 4: 30-35.
25. Rounsaville BJ, Caroll KM, Onken LS. A stage model of behavioral therapies research: getting started and moving on from stage I. Clin Psychol Sci Pract 2001; 8: 133-142.
26. Browne RH. On the use of a pilot sample for sample size determination. Stat Med 1995; 14: 1933-1940.
27. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004; 10: 307-312.
28. Shih WJ, Ohman-Strickland PA, Lin Y. Analysis of pilot and early phase studies with small sample sizes. Stat Med 2004; 23: 1827-1842.
29. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res 2016; 25: 1057-1073.
30. Chow E, Dowyle M, Li K, Bradley N, et al. Mild, moderate, or severe pain categorized by patients with cancer with bone metastases. J Palliat Med 2006; 9: 850-854.
31. Calvert M, Pall M, Hoppit T, Eaton B, Savill E, Sackley C. Health-related quality of life and supportive care in patients with rare long-Term neurological conditions. Qual Life Res 2013; 22: 1231-1238.